A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy
A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy
The primary purpose of this study is to assess the retention rate of perampanel as a reliable
 proxy for overall effectiveness and tolerability in participants aged at least 12 years who
 are prescribed perampanel (for partial onset seizures [POS] with or without secondary
 generalization [SG] or for primary generalized tonic-clonic seizures [PGTCS] associated with
 idiopathic generalized epilepsy [IGE] as first adjunctive to antiepileptic drug (AED)
 monotherapy as part of their routine clinical care.
Inclusion Criteria:

 1. Diagnosis of epilepsy

 2. History of POS with or without SG or PGTCS associated with IGE

 3. Documented POS with or without SG or PGTCS associated with IGE, within the past 12
 months

 4. Previously treated with 1 or 2 AEDs as monotherapy

 5. At least 4 weeks' seizure diary data, or sufficient clinical detail to calculate
 baseline seizure frequency

 Exclusion Criteria:

 1. Episode(s) of status epilepticus within the past 6 months before Screening

 2. Previously treated with 2 or more AEDs in combination (other than during
 cross-titration between AED monotherapies)

 3. Previous or current use of perampanel

 Note: Retrospective inclusions will be allowed but only if the time between the
 initiation of perampanel treatment and the inclusion does not exceed 7 calendar days

 4. Hypersensitivity to perampanel or any of the excipients